Background: Non-alcoholic fatty liver disease (NAFLD) is the most common hepatic disorder worldwide, reaching prevalence up to 90 % in obese patients with type 2 diabetes (T2D), and representing an independent risk factor for cardiovascular mortality. Furthermore, the coexistence of T2D and NAFLD leads to higher incidence of diabetes’ complications and additive detrimental liver outcomes. The existence of a close association between NAFLD and hypovitaminosis D, along with the anti-inflammatory and insulin-sensitizing properties of vitamin D, have been largely described, but vitamin D effects on hepatic fat content have never been tested in a randomized controlled trial. We assessed the efficacy and safety of 24-week oral high-dose vitamin D supplementation in T2D patients with NAFLD. Methods: This randomized, double-blind, placebo-controlled trial was carried out at the Diabetes Centre of Sapienza University, Rome, Italy, to assess oral treatment with cholecalciferol (2000 IU/day) or placebo in T2D patients with NAFLD. The primary endpoint was reduction of hepatic fat fraction (HFF) measured by magnetic resonance; as hepatic outcomes, we also investigated changes in serum transaminases, CK18-M30, N-terminal Procollagen III Propeptide (P3NP) levels, and Fatty Liver Index (FLI). Secondary endpoints were improvement in metabolic (fasting glycaemia, HbA1c, lipids, HOMA-IR, HOMA-β, ADIPO-IR, body fat distribution) and cardiovascular (ankle-brachial index, intima-media thickness, flow-mediated dilatation) parameters from baseline to end of treatment. Results: Sixty-five patients were randomized, 26 (cholecalciferol) and 29 (placebo) subjects completed the study. 25(OH) vitamin D significantly increased in the active treated group (48.15 ± 23.7 to 89.80 ± 23.6 nmol/L, P < 0.001); however, no group differences were found in HFF, transaminases, CK18-M30, P3NP levels or FLI after 24 weeks. Vitamin D neither changed the metabolic profile nor the cardiovascular parameters. Conclusions: Oral high-dose vitamin D supplementation over 24 weeks did not improve hepatic steatosis or metabolic/cardiovascular parameters in T2D patients with NAFLD. Studies with a longer intervention period are warranted for exploring the effect of long time exposure to vitamin D.

No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial / Barchetta, Ilaria; DEL BEN, Maria; Angelico, Francesco; DI MARTINO, Michele; Fraioli, Antonio; LA TORRE, Giuseppe; Saulle, Rosella; Perri, Ludovica; Morini, Sergio; Tiberti, Claudio; Bertoccini, Laura; Cimini, FLAVIA AGATA; Panimolle, Francesca; Catalano, Carlo; Baroni, Marco Giorgio; Cavallo, Maria Gisella. - In: BMC MEDICINE. - ISSN 1741-7015. - ELETTRONICO. - 14:(2016). [10.1186/s12916-016-0638-y]

No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial

BARCHETTA, ILARIA
Primo
;
DEL BEN, Maria
Secondo
;
ANGELICO, Francesco;DI MARTINO, MICHELE;FRAIOLI, Antonio;LA TORRE, Giuseppe;SAULLE, ROSELLA;PERRI, LUDOVICA;TIBERTI, Claudio;BERTOCCINI, LAURA;CIMINI, FLAVIA AGATA;PANIMOLLE, FRANCESCA;CATALANO, Carlo;CAVALLO, Maria Gisella
Ultimo
2016

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is the most common hepatic disorder worldwide, reaching prevalence up to 90 % in obese patients with type 2 diabetes (T2D), and representing an independent risk factor for cardiovascular mortality. Furthermore, the coexistence of T2D and NAFLD leads to higher incidence of diabetes’ complications and additive detrimental liver outcomes. The existence of a close association between NAFLD and hypovitaminosis D, along with the anti-inflammatory and insulin-sensitizing properties of vitamin D, have been largely described, but vitamin D effects on hepatic fat content have never been tested in a randomized controlled trial. We assessed the efficacy and safety of 24-week oral high-dose vitamin D supplementation in T2D patients with NAFLD. Methods: This randomized, double-blind, placebo-controlled trial was carried out at the Diabetes Centre of Sapienza University, Rome, Italy, to assess oral treatment with cholecalciferol (2000 IU/day) or placebo in T2D patients with NAFLD. The primary endpoint was reduction of hepatic fat fraction (HFF) measured by magnetic resonance; as hepatic outcomes, we also investigated changes in serum transaminases, CK18-M30, N-terminal Procollagen III Propeptide (P3NP) levels, and Fatty Liver Index (FLI). Secondary endpoints were improvement in metabolic (fasting glycaemia, HbA1c, lipids, HOMA-IR, HOMA-β, ADIPO-IR, body fat distribution) and cardiovascular (ankle-brachial index, intima-media thickness, flow-mediated dilatation) parameters from baseline to end of treatment. Results: Sixty-five patients were randomized, 26 (cholecalciferol) and 29 (placebo) subjects completed the study. 25(OH) vitamin D significantly increased in the active treated group (48.15 ± 23.7 to 89.80 ± 23.6 nmol/L, P < 0.001); however, no group differences were found in HFF, transaminases, CK18-M30, P3NP levels or FLI after 24 weeks. Vitamin D neither changed the metabolic profile nor the cardiovascular parameters. Conclusions: Oral high-dose vitamin D supplementation over 24 weeks did not improve hepatic steatosis or metabolic/cardiovascular parameters in T2D patients with NAFLD. Studies with a longer intervention period are warranted for exploring the effect of long time exposure to vitamin D.
2016
fatty liver; nafld; type 2 diabetes; vitamin D supplementation; medicine (all)
01 Pubblicazione su rivista::01a Articolo in rivista
No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial / Barchetta, Ilaria; DEL BEN, Maria; Angelico, Francesco; DI MARTINO, Michele; Fraioli, Antonio; LA TORRE, Giuseppe; Saulle, Rosella; Perri, Ludovica; Morini, Sergio; Tiberti, Claudio; Bertoccini, Laura; Cimini, FLAVIA AGATA; Panimolle, Francesca; Catalano, Carlo; Baroni, Marco Giorgio; Cavallo, Maria Gisella. - In: BMC MEDICINE. - ISSN 1741-7015. - ELETTRONICO. - 14:(2016). [10.1186/s12916-016-0638-y]
File allegati a questo prodotto
File Dimensione Formato  
Barchetta_No-effects _2016.pdf

accesso aperto

Note: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0638-y
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 712.53 kB
Formato Adobe PDF
712.53 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/877040
Citazioni
  • ???jsp.display-item.citation.pmc??? 53
  • Scopus 131
  • ???jsp.display-item.citation.isi??? 124
social impact